ClinicalTrials.gg
CompletedNCT06994286Updated Apr 3, 2026

The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.

A Phase 1 interventional study of MT-7117 and Placebo in Healthy Subjects, sponsored by Tanabe Pharma Corporation. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Tanabe Pharma Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of MT-7117 in Chinese healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male Chinese subjects or female Chinese subjects.
  2. Subjects are aged 18 to 55 years, inclusive, at the time of .
  3. Subjects must weigh at least 50 kg and have a (BMI) 19.0 to 26.0 kg/m2 both inclusive at Screening and Day -1.
  4. Subjects must have acceptable clinical conditions in the opinion of the Investigator based upon the results of medical history, physical examination, clinical laboratory tests (biochemistry, hematology, coagulation, and urinalysis), vital signs and a 12-lead at Screening and Day -1.
  5. Subjects are able to provide written informed consent to participate in this study after reading Informed Consent Form (ICF), and after having the opportunity to discuss the study with the Investigator or designee.
  6. In the Investigator's opinion, subjects are able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with presence and history of any (in the opinion of the Investigator) cardiac, hepatobiliary, renal, gastrointestinal, respiratory, psychiatric/neurological, hematopoietic, endocrine, or skin disease.
  2. Subjects with (AST) and/or Alanine aminotransferase (ALT) >=1.5 × (ULN) and/or total >ULN at Screening or Day -1.
  3. Subjects who have a family history of long or short syndrome, hypokalemia, syncope, or Torsades de Pointes.
  4. Subjects with clinically significant 12-lead abnormalities or a QT interval corrected for heart rate using Fridericia's formula (QTcF) >450 msec (male) and >470 msec (female), at Screening or Day -1.
  5. Systolic blood pressure (SBP) outside the range of 90-140 mmHg, diastolic blood pressure (DBP) outside the range of 50-90 mmHg, or pulse rate outside the range of 50-100 bpm, taken in the sitting position at Screening or Day -1.
  6. Presence or history of severe adverse reaction or allergy to any drug or food.
  7. Donation or hemorrhage of 400 mL or more of blood within 12 weeks prior to Screening, or 200 mL or more of blood within 4 weeks prior to Screening.
  8. Subjects who have a positive test for serologic reactions for syphilis, surface (HBs) antigen, Hepatitis B core (HBc) antibody, virus (HCV) antibody, or antibody/antigen at Screening.
  9. Presence or history of drug abuse, or a positive urine test for drugs of abuse at Screening or Day -1.
  10. Presence or history (in the last two years) of alcohol abuse, or intake of more than 28 units/224 g of alcohol weekly for males or 21 units/168 g of alcohol weekly for females or a positive test for alcohol at Screening or Day -1. One unit/8 g is equivalent to a half-pint (280 mL) of beer or one measure (25 mL) of spirits or one glass (125 mL) of wine.
  11. Subjects with presence or history of melanoma and/or presence or history of confirmed dysplastic naevus.
  12. Subjects with a first-degree relative with history of familial melanoma.
  13. Subjects with Fitzpatrick skin type V or VI at Screening (only Part B).
  14. Subjects who have suntanned using tanning beds, phototherapy, or artificial tanning products within 3 months prior to the Day -1. Sunburn due to sunlight may be included in the study if the Investigator judges that there is no problem with the study evaluation.
  15. Subjects who used afamelanotide or melanotan within 6 months prior to the Day -1.
  16. Subjects who used beta-carotene, or any other medications or supplements which may affect skin color, as judged by the Investigator within 3 months prior to Day -1.
  17. Subjects who used any medication (including topical and herbal preparations) other than Medicinal Product (IMP) within 14 days (or 5 half-lives of the drug, whichever is longer) prior to the first dose of IMP.
  18. Subjects who consumed any health food containing St John's Wort within 14 days prior to the first dose of IMP.
  19. Subjects who consumed food or drink containing Seville oranges or grapefruit (including marmalade and fruit juices) within 7 days prior to the first dose of IMP.
  20. Subjects who use tobacco or nicotine-containing products (snuff, chewing tobacco, cigarettes, cigars pipes, e-cigarettes, or nicotine replacement products) within 3 months prior to the first dose of IMP, or positive urine cotinine test at Screening or Day -1.
  21. Subject who underwent surgery known to affect gastrointestinal absorption of the IMP (other than appendectomy and hernia repair/herniorrhaphy/hernioplasty).
  22. Subjects who have participated in another clinical study involving blood sample collection or administration of IMP within 12 weeks prior to .
  23. Subjects who have previously received MT-7117.
  24. Female subjects who are pregnant (positive pregnancy test at Screening or Day -1) or lactating.
  25. Male subjects and female subjects of who don't agree to use as defined in the protocol.
  26. Subjects the Investigator determined ineligible for the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Cohort A-1:MT-7117 100 mg

    single oral dose

    Drug: MT-7117

  • Placebo comparator
    Cohort A-1:Placebo

    single oral dose

    Drug: Placebo

  • Active comparator
    Cohort A-2:MT-7117 300mg

    single oral dose

    Drug: MT-7117

  • Placebo comparator
    Cohort A-2:Placebo

    single oral dose

    Drug: Placebo

  • Active comparator
    Cohort B-1:MT-7117 200mg

    single dose followed by once-daily oral dosing

    Drug: MT-7117

  • Placebo comparator
    Cohort B-1:Placebo

    single dose followed by once-daily oral dosing

    Drug: Placebo

Interventions

  • Oral

    Also known as: Dersimelagon

  • DrugPlacebo

    Oral

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of MT-7117.

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  2. Time to maximum plasma concentration (tmax)of MT-7117.

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  3. Apparent plasma terminal elimination half-life (t1/2) of MT-7117.

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  4. Area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24h) of MT-7117.

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  5. Area under the plasma concentration-time curve from time zero to 48 hours(AUC0-48h) of MT-7117.

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  6. Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-last) of MT-7117.

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  7. Area under the plasma concentration-time curve over the dosing interval (AUC0-τ) of MT-7117.

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  8. Area under the plasma concentration-time curve extrapolated from time zero to infinity (AUC0-∞).

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  9. Terminal elimination rate constant (kel) of MT-7117.

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  10. Apparent oral clearance (CL/F) of MT-7117.

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  11. Apparent volume of distribution during the terminal phase after oral administration (Vz/F) of MT-7117

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  12. Apparent volume of distribution at steady state (Vss/F) of MT-7117

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

  13. Mean residence time (MRT) of MT-7117.

    Time frame: PartA : pre-dose,0.5,1,2,3,4,5,6,8,12,24,48,96 hours (h) post-dose, PartB : Day1,18(pre-dose,0.5,1,2,3,4,5,6,8,12h post-dose), Day2, Day3, Day5,6,8to12,14,16 (before IMP), Day19:24h*, Day20:48h*, Day21:72h* (*after last IMP)

Secondary outcomes

  1. Number of subjects with Treatment-emergent Adverse events (AEs) (including serious AEs [SAEs] and hepatic AEs of special interest [AESIs]).

    Time frame: The time written informed consent is obtained from a subject until the end of the safety follow-up period or the withdrawal of the subject from the study (PartA), or until Day 21 or the withdrawal of the subject from the study (PartB).

07

Study locations

1 site
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, Beijing Municipality 100029, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Jul 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 29, 2025
StartActual
Jun 24, 2025
Primary completionActual
Jul 21, 2025
CompletionActual
Aug 4, 2025
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06994286
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Jun 24, 2025
Primary completion
Jul 21, 2025
Completion
Aug 4, 2025
Last update
Apr 3, 2026

Study contacts

General Manager
study director · Tanabe Pharma Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion